These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20118434)

  • 21. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Side effects. Safety and effectiveness of interferon and ribavirin in HIV+ people co-infected with hepatitis C virus.
    TreatmentUpdate; 2001; 12(8):4-5. PubMed ID: 12132439
    [No Abstract]   [Full Text] [Related]  

  • 23. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
    Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
    Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The adherence in the treatment of chronic hepatitis C].
    Pawłowska M; Halota W
    Pol Merkur Lekarski; 2005 Apr; 18(106):469-72. PubMed ID: 16161937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring depression in patients undergoing alpha-interferon and ribavirin therapy for hepatitis C.
    Wright IA
    Gastroenterol Nurs; 2000; 23(6):275-80. PubMed ID: 11854972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha].
    Acero D; Adrados M; González-Huix F; Figa M
    Gastroenterol Hepatol; 1996 May; 19(5):243-6. PubMed ID: 8752565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe strongyloidiasis during interferon plus ribavirin therapy for chronic HCV infection.
    Paraná R; Portugal M; Vitvitski L; Cotrim H; Lyra L; Trepo C
    Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):245-6. PubMed ID: 10741943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Borderline tuberculoid leprosy and type 1 leprosy reaction in a hepatitis C patient during treatment with interferon and ribavirin.
    Santos M; Franco Edos S; Ferreira PL; Braga WS
    An Bras Dermatol; 2013; 88(6 Suppl 1):109-12. PubMed ID: 24346894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychosis associated with interferon alfa therapy for chronic hepatitis B.
    Tamam L; Yerdelen D; Ozpoyraz N
    Ann Pharmacother; 2003 Mar; 37(3):384-7. PubMed ID: 12639168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C treatment and erotomania.
    García-Toro M; Vilella A; Gili M; Salva J; Roca M
    Gen Hosp Psychiatry; 2012; 34(1):103.e7-103.e10. PubMed ID: 22018768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parkinsonism in Patients With Chronic Hepatitis C Treated With Interferons: Case Reports and Review of the Literature.
    Wangensteen KJ; Krawitt EL; Hamill RW; Boyd JT
    Clin Neuropharmacol; 2016; 39(1):1-5. PubMed ID: 26757310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.
    Mistry N; Shapero J; Crawford RI
    Can J Gastroenterol; 2009 Oct; 23(10):677-83. PubMed ID: 19826642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bronchial casts attributed to the use of pegylated interferon and ribavirin.
    Garcia E; da Silva Junior AF; Schorr F; Hota M; Brizzi RG; da Silva AB
    J Bras Pneumol; 2009 Jul; 35(7):713-6. PubMed ID: 19669011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications.
    Crone C; Gabriel GM
    J Psychiatr Pract; 2003 Mar; 9(2):93-110. PubMed ID: 15985921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychiatric side effects of interferon.
    Yokoyama A; Kimura Y; Shigemura J
    J Toxicol Sci; 1996 Feb; 21(1):93-6. PubMed ID: 8852294
    [No Abstract]   [Full Text] [Related]  

  • 36. How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy.
    Rosedale MT; Strauss SM
    J Am Psychiatr Nurses Assoc; 2010 Nov; 16(6):350-6. PubMed ID: 21659284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute rejection of non-functional renal grafts in dialysis patients after starting treatment with interferon and ribavirin.
    Cavero-Escribano T; Morales-Ruiz E; Manzano-Peña MT; Muñoz-Gómez R; Hernández-Martínez E; Gutiérrez-Martínez E; Praga-Terente M
    Nefrologia; 2014; 34(2):230-4. PubMed ID: 24658199
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon-induced granulomatous lung disease.
    Marzouk K; Saleh S; Kannass M; Sharma OP
    Curr Opin Pulm Med; 2004 Sep; 10(5):435-40. PubMed ID: 15316444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of functional neuroimaging to understanding neuropsychiatric side effects of interferon in hepatitis C.
    Matthews SC; Paulus MP; Dimsdale JE
    Psychosomatics; 2004; 45(4):281-6. PubMed ID: 15232040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-induced sarcoidosis.
    Rubinowitz AN; Naidich DP; Alinsonorin C
    J Comput Assist Tomogr; 2003; 27(2):279-83. PubMed ID: 12703026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.